GABAA receptor positive allosteric modulators

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Friday, June 11, 2021 - 12:30pm

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

Wednesday, June 9, 2021 - 6:00am

We look forward to presenting new data from our Phase 3 clinical program and other important new data on daridorexant.

Key Points: 
  • We look forward to presenting new data from our Phase 3 clinical program and other important new data on daridorexant.
  • Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia.
  • Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages.
  • A benefit-risk assessment of daridorexant for the treatment of insomnia using patient preference data from two phase 3 trials.

Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies

Thursday, June 3, 2021 - 8:00am

Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.

Key Points: 
  • Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of cardiometabolic diseases, today announced key findings with epeleuton from preclinical atherosclerosis studies.
  • Any new therapeutic that can decrease or prevent atherosclerosis is expected to have a significant impact on cardiovascular outcomes, including mortality.
  • In addition to these large reductions in atherosclerosis progression, epeleuton statistically significantly decreased triglycerides, cholesterol and inflammatory markers, including serum interleukin-1 beta (IL-1).
  • The strong effects of epeleuton on atherosclerosis, shown for the first time in these preclinical studies, further emphasises the exciting therapeutic potential of this novel omega 3 drug.

Largest Real-World Study of Bioabsorbable Testosterone Pellets in Men and Women Shows Low Complication Rates Over 7 Years and 1.2 Million Implants

Tuesday, June 1, 2021 - 1:00pm

Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.

Key Points: 
  • Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.
  • The use of testosterone therapy in men has been increasing progressively year over year since the 1990s.
  • The study is the largest reported retrospective study to evaluate the continuation and complication rates of testosterone pellet implants.
  • We are dedicated to helping patients live better, longer by changing the way healthcare is practiced on a global level.

Clearing the Air: A Reduction-Based Solution to Nitrogen Pollution with a Novel Catalyst

Friday, May 21, 2021 - 1:37pm

Among the major pollutants, nitrogen oxide (NOx) accumulation can cause severe respiratory diseases and imbalance in the Earth\'s nitrogen cycle.

Key Points: 
  • Among the major pollutants, nitrogen oxide (NOx) accumulation can cause severe respiratory diseases and imbalance in the Earth\'s nitrogen cycle.
  • Reducing NOx accumulation is, therefore, an issue of utmost importance.\nRecently, the conversion of NOx into harmless or even useful nitrogen products has emerged as a promising strategy.
  • Studies show that for hydroxylamine formation to dominate over N2O formation, very acidic electrolytes with a pH less than 0 are required.
  • "Apart from the applications of hydroxylamine in the nylon industry, it can also be used as an alternative hydrogen carrier.

Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs

Thursday, May 20, 2021 - 7:30pm

b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.

Key Points: 
  • b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.
  • The core of this engine is Saniona\xe2\x80\x99s proprietary IONBASE database, which contains structure-activity data for more than 120,000 compounds.
  • Of these, 20,000 are Saniona\xe2\x80\x99s proprietary compounds, generated over 20 years and enriched for optimal ion channel modulation.\nSAN711 is a first-in-class drug candidate that selectively enhances the effects of GABA-A on \xce\xb13 containing receptors.
  • Saniona\xe2\x80\x99s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated.

Zogenix Launches Dravet Syndrome Community Photo Sharing Charitable Campaign and Contest to Benefit the Dravet Syndrome Foundation and the Epilepsy Foundation

Wednesday, May 19, 2021 - 8:32pm

b'EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ --Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest.

Key Points: 
  • b'EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ --Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest.
  • To participate in the charitable campaign and contest, Zogenix is asking the Dravet syndrome community to share photos of their everyday moments in life with fewer seizures on FINTEPLA (fenfluramine) from now through June 9, 2021.
  • Please read Important Safety Information, including Boxed Warning below.\n"We are constantly inspired by the Dravet community and members\' support for one another.
  • "The FINTEPLA Photo Diary campaign and contest is an opportunity for us to share the hope that we have in between seizures.

Worldwide Cumene Industry to 2026 - Increasing Use of Acetone as a Solvent is Driving Growth - ResearchAndMarkets.com

Tuesday, May 18, 2021 - 3:59pm

b'More than 95% of the global acetone production is used as a by-product of phenol production, which involves cumene use.

Key Points: 
  • b'More than 95% of the global acetone production is used as a by-product of phenol production, which involves cumene use.
  • Automotive parts and medical devices are other applications of MMA.\nThe pharmaceutical industry is continuously expanding, increasing the demand for acetone, thus driving the cumene market.
  • The pharmaceutical market has grown at a rapid pace in 2020 due to the COVID-19 outbreak.\nAdditionally, the growing cosmetic industry is increasing the demand for acetone for use as a solvent.
  • This, in turn, is projected to drive the demand for cumene in the country in the coming years.\n'

Global Toluene Market Growth, Trends, and Forecasts 2021-2026 - Increasing Demand for Benzene & Xylene for Solvent Applications - ResearchAndMarkets.com

Friday, May 14, 2021 - 11:31am

b'The "Toluene Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com\'s offering.\nThe market for toluene is expected to register a CAGR of about 5%, during the forecast period.\nOne of the major factors driving the market studied is the growing usage of toluene as a solvent.

Key Points: 
  • b'The "Toluene Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com\'s offering.\nThe market for toluene is expected to register a CAGR of about 5%, during the forecast period.\nOne of the major factors driving the market studied is the growing usage of toluene as a solvent.
  • China accounted for the largest market for toluene, in the region.
  • China is the largest producer of chemicals, paints and coatings, and adhesives in the Asia-Pacific region.
  • The major companies include Exxon Mobil Corporation, Chevron Phillips, Lyondellbasell Industries NV, Covestro AG, and BASF SE, among others.\n'